---
layout: default
title: Sisomicin
parent: Model Prediction Only (L5)
nav_order: 769
evidence_level: L5
indication_count: 10
---

# Sisomicin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sisomicin: From Bacterial Infections to Osteoarthritis

## One-Sentence Summary

> Sisomicin is an aminoglycoside antibiotic (DrugBank DB12604); no formal original-indication text is on file, but this drug class is used to treat bacterial infections.
> The TxGNN model predicts it may be effective for **Osteoarthritis**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications**, with the model's own rationale noting no known anti-inflammatory or chondroprotective mechanism for this drug class.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented (no India/Taiwan license on file); known clinically as an antibacterial (aminoglycoside class) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.20% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for sisomicin is currently unavailable. Based on known pharmacology, sisomicin is an aminoglycoside antibiotic — a class whose mechanism involves binding the bacterial 30S ribosomal subunit to inhibit protein synthesis. This mechanism has no established link to joint inflammation, cartilage degradation, or the pathophysiology of osteoarthritis.

Aminoglycosides and osteoarthritis belong to entirely different therapeutic domains (antibacterial vs. musculoskeletal/degenerative disease), and there is no known pharmacological, structural, or clinical precedent connecting the two. The TxGNN model's own generated rationale for this candidate explicitly states there is no known anti-inflammatory or cartilage-protective mechanism for this drug class, and that the prediction reflects a graph-embedding association rather than an interpretable biological pathway.

Given the absence of MOA data, clinical trials, and literature, this candidate should be treated as a low-confidence knowledge-graph signal rather than a mechanistically grounded repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate is supported only by a TxGNN embedding score (L5, no clinical trials or literature) and the model's own rationale explicitly finds no plausible mechanistic link between aminoglycoside pharmacology and osteoarthritis. Sisomicin also has no market authorization in India/Taiwan, and core safety data (warnings, contraindications, MOA) are currently missing.

**To proceed, the following is needed:**
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- TFDA/regulatory label warnings and contraindications (currently a Blocking data gap)
- Independent preclinical or mechanistic evidence linking aminoglycosides to osteoarthritis pathophysiology before advancing past S0
- Re-evaluation if clinical trial or literature evidence emerges for this drug–disease pair
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

